Cost Comparisons
Cost-comparisons are used when a new intervention is estimated to have similar clinical benefit as a NICE recommended treatment at a similar cost.
Off
SCHARR-TAG evaluates the comparative efficacy and the difference in total acquisition and administration costs of the new intervention with the NICE recommended treatment.
2022
Cabozantinib for previously treated advanced hepatocellular carcinoma (review of TA582) [ID3917].
Risankizumab for previously treated active psoriatic arthritis [ID1399].
2018
2017
Golimumab after NSAIDs for severe, active, non-radiographic, Axial spondyloarthritis [ID903].